首页|肝动脉栓塞化疗术联合经皮无水乙醇注射治疗少血供肝癌的疗效观察

肝动脉栓塞化疗术联合经皮无水乙醇注射治疗少血供肝癌的疗效观察

扫码查看
目的 探索肝动脉栓塞化疗术联合经皮无水乙醇注射治疗少血供肝癌的疗效.方法 选择2016年4月~2017年4月台州市第一人民医院肝胆外科所收治的36例少血供肝癌患者作为本文的研究对象,将所有患者随机分为实验组与对照组,每组18例.其中实验组患者在采用肝动脉栓塞化疗术联合经皮无水乙醇注射进行治疗,对照组中的患者仅仅采用肝动脉栓塞化疗术治疗.结果 实验组中的患者的治疗有效率为83.33%,对照组中的患者的治疗有效率为44.45%,实验组明显优于对照组,具有统计学意义(P<0.05);实验组中有8名患者出现了明显的发热症状,对照组中患者有9名患者出现了发热症状,2组患者并发症比较差异无统计学意义;实验组中的患者有77.77%的指标出现了较好的变化,而对照组中患者只有66.67%的指标出现了较好的变化,实验组明显优于对照组,差异具有统计学意义(P<0.05);实验组中患者的1、2、3年生存率分别为83.33%(15/18)、66.67%(10/15)、45.45%(5/11),对照组中患者的1、2、3年生存率分别为61.11%(11/18)、36.36%(4/11)、28.57%(2/7),实验组中患者在生存时间明显优于对照组,差异具有统计学意义(P<0.05).结论 肝动脉栓塞化疗术联合经皮无水乙醇注射治疗少血供肝癌效果显著.
Therapeutic effect of transcatheter arterial chemoembolization combined with percutaneous ethanol injection on small donor liver cancer
Objective To explore the effect of transcatheter arterial chemoembolization combined with percutaneous ethanol injection in the treatment of small blood donor liver cancer. Methods We selected 36 cases of blood supply from Hepatobiliary Surgery during April 2016 to April 2017, Liver cancer patients as the object of this study, all patients were randomly divided into experimental group and control group, each group of 18 cases. The patients in the experimental group were treated with transcatheter arterial chemoembolization combined with percutaneous ethanol injection. The patients in the control group were treated with transcatheter arterial chemoembolization. Results The effective rate of treatment was 83.33% in the experimental group and 44.45% in the control group. The experimental group was significantly better than the control group, the difference was statistically significant (P<0.05). The experimental group and the control group had no obvious difference. The experimental group and the control group had no obvious difference of the patients with 77.77% of the patients showed a good change in the target group, and only 66.67% of the patients in the control group showed a better change in the patient's index, the experimental group was significantly better than the control group, the statistics were significantly different (P<0.05). The 1, 2, and 3-year survival rates were 83.33% (15/18), 66.67% (10/15) and 45.45% (5/11) in the experimental group, The 1, 2, and 3 year survival rates were 61.11% (11/18), 36.36% (4/11) and 28.57% (2/7) respectively. The survival time of the patients in the experimental group was significantly better than that in the control group (P<0.05). Conclusion Transcatheter arterial chemoembolization combined with percutaneous ethanol injection is effective in the treatment of small blood donor liver cancer, which should be popularized in clinical practice.

hepatic artery thrombosis chemotherapyanhydrous ethanolless blood donor liver cancerliver function

谢觉醒、罗雯、郏鹏

展开 >

台州市第一人民医院 普外科,浙江 台州 318020

台州市第一人民医院 放射科,浙江 台州 318020

肝动脉栓塞化疗术 无水乙醇 少血供肝癌 肝功能

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(11)
  • 1
  • 8